News & Events
Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
WATERTOWN, Mass., June 22, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the
More News
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.
Facility significantly increases future financial and operational flexibility Up to $200M available, with $30 million drawn at close and additional $80 million...
read more
Disc Medicine Announces Multiple Presentations Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting
Oral presentation of complete data from Phase 1b trial of DISC-0974 in anemia of myelofibrosis (MF) Poster presentations across all programs, including...
read more
Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
Alignment with the FDA across all proposed study parameters, providing a clear development path to registration Agreement on proposed primary endpoint of...
read more